How Does Calibrate Ensure Zepbound® Is Prescribed Safely? | Calibrate

What Is Zepbound and Why Does Safe Prescribing Matter?

Zepbound received FDA approval on November 8, 2023, for chronic weight management in adults, making it the first dual GIP/GLP-1 receptor agonist cleared specifically for obesity treatment in the United States [1]. Because it works on two incretin pathways simultaneously, it produces larger average weight loss than earlier single-agonist agents, but it also carries a distinct safety profile that demands careful prescriber oversight.

In SURMOUNT-1 (N=2,539), tirzepatide 15 mg produced 20.9% mean body-weight reduction at 72 weeks compared with 3.1% in the placebo group (P<0.001) [2]. That magnitude of effect is clinically meaningful, but it comes alongside a gastrointestinal side-effect burden and a boxed warning for thyroid C-cell tumors observed in rodent studies, two reasons that safe prescribing protocols exist.

The Regulatory Foundation

The FDA's prescribing information for Zepbound specifies that the drug is indicated for adults with an initial BMI ≥30 kg/m², or ≥27 kg/m² with at least one weight-related condition such as hypertension, type 2 diabetes, or dyslipidemia [1]. Calibrate's clinical protocols mirror this guidance directly. No prescription is issued to a patient who does not meet these thresholds.

Why Telehealth Prescribing Requires Extra Rigor

Telehealth platforms face heightened scrutiny from regulators precisely because the physical examination is conducted asynchronously or by video. The DEA's 2023 proposed rules on telemedicine prescribing [3] and FDA's ongoing oversight of GLP-1 compounding [4] underscore that telehealth prescribers carry the same standard-of-care obligations as in-person clinicians. Calibrate's framework is built to satisfy that standard.

How Calibrate Screens Patients Before Prescribing Zepbound

Every Calibrate member who requests Zepbound goes through a multi-layer intake process before a physician ever reviews a prescription. This is not a self-reported questionnaire alone. It includes physician-reviewed labs, a structured medical history, and a contraindication checklist aligned with the Zepbound FDA label [1].

Step 1: Medical History and Comorbidity Review

Calibrate's intake form captures BMI, weight history, prior weight-loss attempts, current medications, and a full comorbidity list. The system flags conditions that require additional clinical review before prescribing, including:

• Personal or family history of medullary thyroid carcinoma (MTC)
• Personal or family history of Multiple Endocrine Neoplasia syndrome type 2 (MEN2)
• Active or history of pancreatitis
• Severe gastrointestinal disease
• Pregnancy or plans to become pregnant within the next two months

The Zepbound label carries a boxed warning for thyroid C-cell tumors based on rodent carcinogenicity data, and the drug is contraindicated in patients with a personal or family history of MTC or MEN2 [1]. Calibrate physicians will not prescribe Zepbound to any patient who screens positive for these histories.

Step 2: Required Laboratory Testing

Lab results are required before a prescription is generated. The standard Calibrate panel for Zepbound candidates includes:

• Comprehensive metabolic panel (CMP)
• Hemoglobin A1c (HbA1c)
• Fasting lipid panel
• Thyroid-stimulating hormone (TSH)
• Complete blood count (CBC)

This requirement aligns with the American Association of Clinical Endocrinology (AACE) obesity guidelines, which recommend baseline metabolic and thyroid evaluation before initiating GLP-1 class therapy [5]. Lab results older than 90 days are not accepted; members must submit current values.

Step 3: Physician Review and Prescribing Decision

A board-certified physician reviews every intake file before a prescription is approved. No algorithm auto-approves Zepbound. The physician confirms that:

1. BMI meets FDA threshold (≥30 or ≥27 with comorbidity)
2. No absolute contraindications are present
3. Labs are within acceptable ranges
4. Current medications do not create a clinically significant interaction risk

The Endocrine Society's 2023 clinical practice guideline on obesity pharmacotherapy states: "Anti-obesity medications should be prescribed only when the anticipated benefits outweigh the risks, and prescribers should conduct a thorough evaluation of medical history, current medications, and metabolic status before initiating therapy" [6]. Calibrate's protocol operationalizes exactly this standard.

How Calibrate Structures the Zepbound Dosing Schedule

Calibrate follows the FDA-approved titration schedule precisely, without compression or acceleration unless a physician explicitly approves a deviation based on tolerability data.

Standard Titration Ladder

The approved dose escalation for Zepbound is [1]:

• Weeks 1 to 4: 2.5 mg once weekly
• Weeks 5 to 8: 5 mg once weekly
• Weeks 9 to 12: 7.5 mg once weekly (if tolerated)
• Weeks 13 to 16: 10 mg once weekly (if tolerated)
• Weeks 17 to 20: 12.5 mg once weekly (if tolerated)
• Week 21 onward: 15 mg once weekly (maintenance, if tolerated)

Each escalation is contingent on tolerability. Calibrate physicians can pause a patient at any rung on this ladder based on side-effect reports submitted through the app or during check-in visits.

Dose Pauses and De-escalation

Gastrointestinal side effects are the most common reason for dose pauses. In SURMOUNT-1, nausea occurred in 30.5% of patients on tirzepatide 15 mg vs. 6.3% on placebo, and vomiting occurred in 18.4% vs. 2.2% [2]. Calibrate's clinical team monitors these events at every check-in and will de-escalate dose or extend time at a lower dose when a patient reports persistent nausea, vomiting, or significant food intolerance.

De-escalation is not a failure. Reaching 10 mg still produced 19.5% weight loss in SURMOUNT-1, and 7.5 mg produced 17.8% [2]. The best dose is the highest dose a patient tolerates consistently.

Ongoing Monitoring Protocols After Prescribing

Safe prescribing does not end at the first prescription. Calibrate's monitoring cadence keeps physicians informed throughout the treatment course.

Check-In Schedule

• Week 4: First follow-up. Physician or nurse reviews tolerability, confirms dose escalation to 5 mg is appropriate, asks about injection technique.
• Week 8: Second follow-up. Reviews GI side effects, weight change, flags any new symptoms.
• Week 12: Third follow-up. Assesses continued eligibility, reviews any new medications started since intake.
• Quarterly thereafter: Ongoing monitoring for all members on maintenance dosing.

Members can also message the clinical team asynchronously between scheduled check-ins. Any report of severe abdominal pain triggers a same-day clinical review given the risk of pancreatitis associated with GLP-1 class drugs [1].

Lab Monitoring During Treatment

Repeat labs are ordered at 3 months and 6 months for members with baseline metabolic abnormalities. HbA1c is re-checked in members with type 2 diabetes at 3 months because tirzepatide can lower blood glucose substantially. In SURMOUNT-2, which enrolled adults with type 2 diabetes (N=938), tirzepatide 15 mg reduced HbA1c by 2.4 percentage points vs. 0.5 for placebo at 72 weeks [7]. Hypoglycemia risk is real in this population, especially in patients also taking sulfonylureas or insulin, and Calibrate physicians adjust those background medications proactively.

Medication Interaction Screening

Calibrate's intake system flags a defined list of drug classes that warrant physician review before Zepbound is approved. These include:

• Insulin and sulfonylureas (hypoglycemia risk potentiation)
• Oral contraceptives (gastric emptying delay may reduce absorption; backup contraception is advised for four weeks after each dose escalation, consistent with the Zepbound label) [1]
• Warfarin and narrow therapeutic index drugs (gastric emptying changes can alter absorption kinetics)

The FDA label specifically notes that Zepbound slows gastric emptying and may affect the absorption of co-administered oral medications [1]. Calibrate's prescribing checklist addresses this directly.

Contraindications and Patient Populations Who Are Not Eligible

Some patients will be declined for Zepbound through Calibrate's process. This is not a flaw in the system. It reflects the contraindication profile in the FDA label and the clinical judgment of the reviewing physician.

Absolute Contraindications

• Personal or family history of MTC
• Personal or family history of MEN2
• Known hypersensitivity to tirzepatide or any excipient in the formulation [1]

Conditions Requiring Case-by-Case Physician Review

• Active or history of pancreatitis (FDA label advises caution; GLP-1 drugs have been associated with pancreatitis, though causality in humans remains under investigation) [8]
• Severe gastroparesis or other severe GI motility disorders
• Pregnancy (Zepbound should be discontinued at least two months before a planned pregnancy per FDA label guidance) [1]
• Severe renal impairment (no dose adjustment required per label, but close monitoring is warranted) [1]
• Active gallbladder disease (cholelithiasis rates were elevated in SURMOUNT-1) [2]

The clinical decision framework Calibrate applies maps each of these conditions to one of three dispositions: approve, approve with modification (dose adjustment, additional monitoring, or co-medication change), or decline with referral to in-person care. This three-tier triage model ensures that borderline cases receive individualized physician review rather than an automated binary outcome.

What Happens If a Patient Experiences a Serious Adverse Event?

Calibrate's clinical escalation pathway is defined before a prescription is issued. If a member reports symptoms consistent with a serious adverse event, the following steps occur:

Pancreatitis Protocol

Severe persistent abdominal pain, especially with radiation to the back, triggers an immediate clinical hold on the prescription and instructions to seek emergency evaluation. The FDA label states that Zepbound should be discontinued and not restarted if pancreatitis is confirmed [1]. The Calibrate clinical team follows this instruction without exception.

Thyroid Nodule or Neck Mass

Any member who reports a neck mass, dysphagia, hoarseness, or other symptoms consistent with thyroid pathology is referred to an endocrinologist. The boxed warning in the Zepbound label advises patients to report these symptoms promptly [1], and Calibrate reinforces this during onboarding education.

Acute Kidney Injury

Severe vomiting and diarrhea can cause volume depletion and, in vulnerable patients, acute kidney injury. Calibrate's clinical guidance instructs members to stop the injection and seek care if they cannot maintain oral hydration for more than 24 hours, consistent with FDA label recommendations [1].

How Calibrate's Approach Compares to Standard Clinical Guidelines

The American Association of Clinical Endocrinology 2023 obesity guidelines recommend that pharmacotherapy for obesity be initiated with careful patient selection, baseline evaluation, and structured follow-up, and that all prescribers document the clinical rationale for each medication choice [5]. The Obesity Medicine Association similarly calls for individualized treatment plans, monitoring of metabolic parameters, and clear stopping rules [9].

Calibrate's protocol matches all three of these framework pillars. Physician review is documented in the medical record for every prescription. Baseline labs are required, not optional. Follow-up is scheduled, not left to patient initiative.

The Endocrine Society guideline authors wrote: "Shared decision-making between the clinician and the patient is essential; patients should understand the expected benefits, likely side effects, and the importance of sustained use for sustained effect" [6]. Calibrate's onboarding education module covers all three of these points before a member's first injection.

How Calibrate Handles Zepbound Supply Shortages and Compounded Tirzepatide

The FDA placed tirzepatide on its drug shortage list in late 2023, which prompted a surge in compounded tirzepatide products from 503A and 503B pharmacies. Calibrate does not prescribe compounded tirzepatide from unregulated sources. The FDA has stated clearly that compounded drugs are not FDA-approved and do not undergo the same manufacturing quality controls as brand-name Zepbound [4].

Calibrate sources Zepbound exclusively through licensed, FDA-regulated pharmacies. When shortage-related supply constraints affect fill times, Calibrate physicians discuss the clinical options with affected members, which may include a temporary dose hold, a switch to semaglutide (Wegovy), or a pause in therapy with a clear restart plan.

The FDA removed tirzepatide from its shortage list in March 2025 [4]. Members currently on compounded tirzepatide from other platforms should be aware that the FDA has indicated that pharmacies may no longer lawfully compound tirzepatide now that the shortage designation has been lifted.

Insurance Coverage, Prior Authorization, and Out-of-Pocket Cost

Calibrate's clinical team prepares prior authorization documentation for members pursuing insurance coverage. Zepbound's list price is approximately $1,059.87 per month for the 15 mg dose without insurance, though manufacturer savings programs (Eli Lilly's Zepbound savings card) may reduce this to $550 per month for eligible commercially insured patients, and as low as $399 per month for cash-pay patients through the Lilly direct program [10].

Prior authorization approval typically requires documentation of BMI, qualifying comorbidities, and prior treatment attempts. Calibrate physicians document all of these in the clinical record, which is submitted with the PA request.